Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 1.00 |
| ▸ | CDK7 | P50613 | 9/20 | 1.00 |
| ▸ | CCNH | P51946 | 9/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 7/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.76 |
| ▸ | CDK2 | P24941 | 15/20 | 0.76 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.76 |
| ▸ | CDK9 | P50750 | 14/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24584360 | 1.00 | CCNK (1.00) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL25591386 | 0.88 | CCNK (0.78) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL25594512 | 0.88 | CCNK (0.78) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL24839544 | 0.87 | CCNK (1.00) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL25591704 | 0.86 | CCNK (0.76) | CCNKCDK12CDK7CCNHMNAT1 | |
| Trifluoroacetic Acid SCHEMBL30260987 | 0.86 | CCNK (0.74) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL24839704 | 0.85 | CCNK (1.00) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL30204018 | 0.85 | CCNK (1.00) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL29492550 | 0.85 | CCNK (1.00) | CCNKCDK12CDK7CCNHMNAT1 | |
| SCHEMBL25605311 | 0.85 | CCNK (1.00) | CCNKCDK12CDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | RECURSION PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-20240124504-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-18 | — | — | US | disclosed |
| EP-4269403-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| CN-116745277-A | Aromatic heterocyclic compound, pharmaceutical composition and application thereof | 湃隆生物科技有限公司（香港） | 2023-09-12 | — | — | CN | disclosed |
| CN-116670123-A | Aromatic heterocyclic compound, pharmaceutical composition and application thereof | 湃隆生物科技有限公司（香港） | 2023-08-29 | — | — | CN | disclosed |
| WO-2022134642-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 湃隆生物科技有限公司（香港） | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK17, CDK8 | CCNK 39/4885CDK12 38/4885CDK7 1/4885 |
| US-20240124504-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | CDK7, CDK17, CDK8 | CCNK 33/4885CDK12 35/4885CDK7 1/4885 |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | CDK7, CDK17, CDK1 | CCNK 4/4885CDK12 8/4885CDK7 1/4885 |
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK8, CDK6 | CCNK 19/4885CDK12 33/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.